Health Canada can now approve drugs by relying on trusted foreign regulators' reviews instead of repeating the full examination

Plain-language summary · AI-assisted

A new federal order lets drug manufacturers ask Health Canada to treat certain parts of its review as already completed, based on a decision or review document from an approved foreign regulator. This applies to new drug submissions, abbreviated new drug submissions, and supplements, covering non-clinical, clinical, and chemistry/manufacturing information. Manufacturers must show their drug matches the foreign-approved drug in strength, dosage form, route, and medicinal ingredient, and that any differences would not affect safety or effectiveness. They must also share foreign labels, post-market measures, and disclose any withdrawn or refused foreign applications for similar drugs. Eligibility depends on the drug class and foreign regulator appearing on a published government List; Health Canada must still conduct its own review of information that does not qualify or where differences exist. Manufacturers using this pathway must provide additional supporting information to Health Canada on request.

Who this affects
drug manufacturers filing new drug submissions · manufacturers filing abbreviated new drug submissions · manufacturers filing supplements to drug submissions · pharmaceutical companies seeking Canadian market approval